Ella A. Kazerooni M.D. is a Professor of Radiology and Internal Medicine at the University of Michigan Medical School, specializing in cardiothoracic radiology, and the Associate Chief Clinical Officer for Diagnostics for the University of Michigan Medical Group. After medical school and diagnostic radiology residency at the University of Michigan, she completed a fellowship in thoracic radiology at Massachusetts General Hospital/Harvard Medical School. She is a past president of the American Roentgen Ray Society, the Association of University Radiologists, the Society of Thoracic Radiology and the Radiology Alliance for Health Services Research, a past Trustee of the American Board of Radiology and has served on the ACR Board of Chancellors.

With a Master’s degree in Clinical Research Design & Statistical Analysis, Dr. Kazerooni’s research focuses on the development and evaluation of advanced imaging technologies applied to the heart and lungs, including lung cancer screening, coronary artery and aortic disease, pulmonary embolism, and diffuse lung diseases. Her work in clinical and translational research earned her the University of Michigan Medical School’s prestigious Clinical and Health Services Researcher of the year award. She has given over 650 lectures, has over 400 peer-reviewed manuscripts, 30 book chapters and 4 books.  Dr. Kazerooni is a highly sought after speaker and international expert in cardiothoracic radiology, with a focus on diffuse lung diseases and lung cancer screening. She chair’s the Lung Cancer Screening Registry at the American College of Radiology, led the development of the LungRADS schema for the interpretation and management of lung cancer screening, and is vice-chair of the Lung Cancer Screening Guideline group at the National Comprehensive Cancer Network. As founding Chair of the National Lung Cancer Roundtable at the American Cancer Society. Dr. Kazerooni is committed to the mission to create lung cancer survivors, to increase the uptake of lung cancer screening and incidental lung nodule management towards early detection, to bring biomarker-based therapies to patients with advanced lung cancer, and to do so in a patient-first manner, towards eliminating the stigma commonly faced by patients in their lung cancer journey.